Athira Pharma, Inc. (NASDAQ:LONA) Given Consensus Rating of “Hold” by Analysts

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have received an average recommendation of “Hold” from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $15.00.

A number of brokerages recently weighed in on LONA. Mizuho upgraded shares of Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective for the company in a report on Thursday, February 19th. Zacks Research upgraded shares of Athira Pharma to a “hold” rating in a report on Friday, February 27th. Wall Street Zen upgraded shares of Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Piper Sandler began coverage on shares of Athira Pharma in a report on Wednesday. They issued an “overweight” rating and a $20.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Athira Pharma in a report on Monday, May 11th.

Insiders Place Their Bets

In related news, CEO Mark James Litton sold 5,156 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $5.37, for a total value of $27,687.72. Following the completion of the transaction, the chief executive officer directly owned 57,926 shares in the company, valued at $311,062.62. The trade was a 8.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 9,110 shares of company stock valued at $48,921. 25.73% of the stock is owned by insiders.

Athira Pharma Stock Performance

Shares of LONA opened at $9.67 on Wednesday. The stock has a 50 day moving average of $9.72. Athira Pharma has a 52 week low of $2.64 and a 52 week high of $14.21. The company has a market cap of $90.80 million, a PE ratio of -1.86 and a beta of 1.98.

Athira Pharma (NASDAQ:LONA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.73) EPS for the quarter. As a group, sell-side analysts forecast that Athira Pharma will post -3.75 EPS for the current fiscal year.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.